Minover

Minover is a private Chinese biopharmaceutical company focused on discovery and development of novel small-molecule medicines. Publicly available sources associate the Minover name with Nanjing Minowei Pharmaceutical Technology Co., Ltd. and its wholly owned Wuxi subsidiary, and also indicate branding as Minova Pharma or 迈诺威医药. The company appears to concentrate on disorders affecting quality of life, including neuropsychiatric conditions, with MI078 in Phase 2 development for postpartum depression in China. Patent and company-profile sources also suggest activity in consumer or aesthetic medicine-related products. Because English-language primary company materials are limited, several fields below should be treated as best-effort and partially inferred from secondary sources.